The clinical efficacy of oral hydroxyurea (HU) in adults and children with sickle cell anemia (SCA) cannot solely be explained by its ability to enhance fetal hemoglobin (HbF) expression. Since increased adherence of sickle red blood cells to vascular endothelium is a possible contributing factor to vasoocclusive crisis (VOC), we explored the effect of HU on human endothelial cell (EC) lines (TrHBMEC and EA-hy 926). We demonstrated that HU, in a dose-dependent and reversible manner, significantly decreased (up to threefold) the release of endothelin-1 (ET-1), a vasoconstrictor peptide through downregulation (up to three-fold) of ET-1 gene expression. This finding is of therapeutic relevance as SCA patients exhibit elevated serum levels of ET-1 during episodes of VOC and levels correlate with disease severity. Unexpectedly, HU upregulated (up to three-fold) the expression of membrane-bound intercellular cell adhesion molecule 1 (mbICAM-1) and its soluble form (sICAM-1) with a parallel increase in ICAM-1 mRNA expression. Although ICAM-1 does not appear to be involved in the sickle cell adhesion to vascular endothelium, it may exacerbate vaso-occlusion by promoting leukocyte adhesion. The HU-induced increase in mbICAM-1 may appear inconsistent with the clinical benefits confered by HU. However, both the increase in sICAM-1-and HU-induced leukocyte reduction in patients, may counteract the potentially detrimental effect of elevated mbICAM-1 expression. Also HU reduces the expression of vascular cell adhesion molecule (VCAM-1) on EC. Since HU reduces the very late antigen 4-positive reticulocytes in SCA patients, a ligand for VCAM-1, HU-induced downregulation of VCAM-1 on EC will very likely decrease the reticulocyte-endothelium adhesion. Thus, HU, apart from inducing HbF expression in the red cell, also affects the expression profile of EC compartment.
INTRODUCTION
Hydroxyurea (HU) is an inhibitor of ribonucleotide reductase, a rate-limiting enzyme, involved in the conversion of ribonucleotides into deoxyribonucleotides. Thus, HU affects cells that are actively synthesizing DNA. HU has long been used to treat a variety of neoplastic disorders including chronic granulocyte leukemia, head and neck cancer and polycythemia vera. In addition to inhibiting ribonucleotide reductase, HU affects gene expression, most notably of the human fetal globin genes. HU enhances the expression of fetal hemoglobin (HbF) in cell culture and primate models. 1, 2 As sickle cell anemia (SCA) patients with high levels of HbF experience a less severe form of the disease, HU therapy was tested in several clinical trials in patients with SCA to induce HbF expression.
In clinical trials, HU therapy had many positive clinical and biological benefits. The clinical benefits include a large reduction in the frequency of hospitalizations, pain episodes, acute chest syndromes (ACS) and blood transfusions. 3 Biologically, HU therapy increased HbF levels, F reticulocyte count, F-cell count, mean corpuscular volume, red blood cell (RBC) survival and deformability, oxygen affinity, cation content and hydration. Also, HU decreased the mean corpuscular Hb concentration, hemolysis, number of irreversibly sickled red cells, KCl cotransport [4] [5] [6] [7] [8] expression of red cell adhesion molecules and their in vitro adhesion. 9 Although the efficacy of HU therapy in SCA was believed to be mediated primarily through the induction of HbF expression, the improvement in clinical symptoms preceding any significant increase in HbF raises the possibility that HU may also act through other mechanisms. 10 In SCA patients treated with HU, sickle cell-endothelial cell (EC) adherence decreased prior to any significant increase in HbF. 11 This suggests that HU may affect the RBC and/or EC surface.
Very few studies have explored the effect of HU on EC function. 9 ECs play a major role in vasoadhesion of a variety of blood cells via cell surface adhesion molecules, such as intercellular cell adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). RBCs from SCA patients (SS RBCs) have the predilection to adhere to the endothelial surface as compared to the RBCs from normal subjects (AA RBCs). 12 Such abnormal RBC-endothelial adherence is believed to initiate a painful vaso-occlusive crisis (VOC), a physiopathologic hallmark of the disease. ECs respond to numerous extracellular signals such as vasoactive factors (ET-1 and NO), proinflammatory cytokines (TNFa, interleukin 1 and IFNg), oxidants and hypoxia. 13 Variations in these signals can affect the EC characteristics and thereby contribute to the unpredictable occurrences of VOC. The resulting endothelial injury, indicated by the presence of activated ECs circulating in the blood of SCA patients, 14 could contribute to additional complications. Here, we evaluate the effects of HU on vascular ECs.
RESULTS

HU Reduces ET-1 mRNA and Peptide Expression
TrHBMEC and EA-hy 926 cells were exposed to HU at a concentration (250 mM) similar to the in vivo HU levels of treated SCA patients. Experiments were performed both in the absence and in the presence of 100 U/ml of TNFa and IFNg (a concentration that induces the expression of adhesion molecules, but does not affect the synthesis and release of endothelin-1, ET-1). The presence of proinflammatory cytokines allowed simulation of the in vivo inflammatory status of SCA patients.
Under basal culture conditions, the amount of ET-1 peptide released into the medium was comparable for the two endothelial cell types: 7817176 pg/ml for TrHBMEC, 5057128 pg/ml for EA-hy 926 ( Figure 1 ) and was not significantly altered by the presence of proinflammatory cytokines. The presence of HU significantly reduced ET-1 peptide release from TrHBMEC (4117125 pg/ml) and EA-hy 926 cells (325785 pg/ml) and the magnitude of the reduction was similar in the presence of cytokines (4797129, 4057159 pg/ml, respectively).
In the presence of HU (48 h exposure), there was also a decrease in ET-1 mRNA as assessed by the real-time quantitative PCR (Figure 2) . In TrHBMEC cells, there was a significant reduction in ET-1 mRNA level (57719.6% of the basal value), whereas reduction was greater (38712.2% of the basal value) when HU treatment was applied in the presence of two inflammatory cytokines (Figure 2a) . Although a trend towards decrease was observed for EA-hy 926 cells with a residual mRNA level of 35713.3% of the basal value with HU alone a difference was noted in the presence of both HU and cytokines. The decrease was much less pronounced (only 52712.4% of the basal value) in these cells. Such differences may represent the difference in cell lines.
To explore if ET-1 expression is HU dose dependent, the TrHBMEC cells were incubated with HU at concentrations from 62.5 to 500 mM (beyond 500 mM, HU was found to be consistently lethal for endothelial cells). Both the decrease in ET-1 peptide release ( Figure 3a ) and mRNA abundance ( Figure 3b ) were found to be HU dose dependent. The decrease in mRNA was much more prominent than the peptide release for HU concentrations of 250 mM or lower, especially in the presence of inflammatory cytokines.
HU Effect on ET-1 mRNA Expression is Reversible
To study whether the effect of HU on ET-1 peptide release and mRNA concentration was reversible, EA-hy 926 cells were incubated for 48 h with HU (250 mM) and then in HUfree DMEM growth medium both with and without cytokines ( Figure 4 ). Since TrHBMEC cells started to detach from 72 h onwards and very few cells remained adhered after 96 h treatment with HU, reversible effect of HU was tested only with EA-hy 926 cells. Nevertheless, the overall After exposure of cells to HU (without cytokines) for 48h, the amount of ET-1 mRNA was 3972.9% of the basal level but rose to 76.574.9% 48 h after the removal of HU from the medium. Exposure of cells to HU in the presence of cytokines resulted in decrease of ET-1 mRNA (35.474.9% of the basal level) and after its removal, recovery was almost complete (89.2718.4% of control) (Figure 4) .
With the same experimental setup, we examined the status of ET-1 peptide release into the culture supernatant. Under basal conditions (control), ET-1 secretion was 900.27234 pg/ml and in the presence of HU, it decreased to 457.47159.1 pg/ml (Figure 5a ). At 48 h after the removal of HU, the ET-1 peptide release remained low (399.17145.8 pg/ml). A similar trend was noted in the presence of cytokines (Figure 5b) .
Thus, HU inhibited synthesis and release of ET-1 peptide in a dose-dependent manner from two different endothelial cell lines both in the presence and absence of proinflammatory cytokines. Our data further demonstrated that the to values obtained for cytokines alone (4.771.3) (Figure 7a ). Exposing the cells for 48 h to HU alone, led to a 3.170.3-fold increase in ICAM-1 mRNA. Under the same conditions, the cytokines alone caused a 2.170.6-fold increase in the ICAM-1 mRNA, whereas in combination with HU, the increase was a 673.7-fold.
In separate time-course experiments, we observed that the magnitude of increase in ICAM-1 mRNA by cytokines and HU peaked at 24 and 48 h, respectively. In addition, we noted that HU provoked a sustained increase in ICAM-1 mRNA abundance but only in the presence of proinflammatory cytokines.
HU Decreases Release of IL-6
A slight decrease in the release of IL6 was observed in HUtreated cells (8.771.5 pg/ml) as compared to nontreated cells (11.670.4 pg/ml) (Figure 6d ). In the presence of proinflammatory cytokines and HU, the release of IL-6 (8.272.9 pg/ml) was significantly lower than that by cells treated with cytokines alone (15.672.9 pg/ml).
HU Downregulates the Membrane-bound VCAM-1 Expression without Affecting sVCAM-1 Release
The maximal expression of membrane-bound VCAM-1 (mbVCAM-1) in the presence of HU and cytokines was between 12 and 24 h (data not shown).
A 24 h exposure of TrHBMEC cells to HU alone (MFI 0.3) did not modify the expression of mbVCAM-1. In the presence of proinflammatory cytokines, 50% of the cells became positive for mbVCAM-1 (MFI 4.1), as assessed by the flow cytometry. Addition of HU to cytokine-treated cells reduced the MFI to 2.9 and the percentage of mbVCAM-1-positive cells to 36% (Figure 8a) .
A 24 h exposure of TrHBMEC cells to only HU did not modify the release of sVCAM-1 into the culture supernatant (4.170.8 ng/ml as compared to 4.570.6 ng/ml for the untreated control). Cytokines increased the level of sVCAM-1 release (8.473.3 ng/ml), but the presence of HU in addition to cytokines had no significant effect (7.672.4 ng/ml) (Figure 8b ).
VCAM-1 mRNA Expression is Downregulated by HU VCAM-1 mRNA was studied by real-time quantitative PCR. Results are means7SD of fold induction as compared to control. ECs exposed for 24 h to proinflammatory cytokines produced a large increase (25-fold) in VCAM-1 mRNA abundance (Figure 9a ). When these cells were treated with HU and cytokines together, the magnitude of increase in VCAM-1 mRNA was limited to 15-fold. The effects of various concentrations of HU (62.5, 125, 250 and 500 mM) in the presence of cytokines were tested and the decrease in VCAM-1 mRNA abundance was HU dose dependent ( Figure  9b ).
Production of NO and Expression of NO Synthase
Only trace amounts of NO derivatives were detected in the culture supernatant in all the experimental conditions. The constitutively synthesized endothelial NO synthase (eNOS) did not vary between the different culture conditions (4020759 pg/ml for untreated control, 39997124 pg/ml for HU treated cells, 40717157 pg/ml for cytokines treated cells and 41697103 pg/ml for HU-and cytokine-treated cells). We could not detect the inducible NOS (iNOS) mRNA in these experiments, although the control mRNA from A549 cell line provided the expected positive signal.
Effect of HU on Endothelial Cell Cycle Changes
The cytostatic effect of HU was examined under our experimental conditions. Both the TrHBMEC and EA-hy 926 cells were allowed to reach a confluent monolayer before their exposure to various agent. A significant Other stimuli such as TNFa, a proinflammatory cytokine, induces ET-1 release from a variety of ECs in a time and concentration-dependent manner accompanied by a corresponding increase in the transcriptional rate of the ET-1 gene. 18 Interestingly, ET-1 mRNA production and ET-1 peptide release increase when ECs from bovine pulmonary artery were exposed to plasma from patients with ACS. 19 Similarly sickle erythrocytes specifically stimulate the expression of the ET-1 gene and production of the peptide in human ECs in culture. 20 In animal models ET-1: (i) causes accumulation of leukocytes in the pulmonary microvasculature, 21 (ii) increases vascular permeability in the presence of leukocytes in perfusion 22 and (iii) results in a time-and dose-dependent sequential entrapment of platelets and neutrophils in the pulmonary circulation. 23 ET-1 activates the Gardos channel in mouse erythrocytes. 24 This channel activation, in the context of sickle red cell, is expected to dehydrate these cells. Important clinical findings include significantly elevated levels of ET-1 in SCA patients during the episodes of painful crisis 25, 26 and ACS. Also, the extent of ET-1 increase correlates with disease severity. 19 These experimental and clinical observations suggest that ET-1 might play an important role in the cycle of ischemia and inflammation that initiates and sustains a painful crisis in sickle cell patients. Local ET-1 levels in the microvasculature are probably much higher than those in the systemic circulation, and may contribute to the prolonged local vasospasm and inflammation and thus to vaso-occlusive events, the hallmark of the sickle cell disease. Our finding that HU significantly suppresses ET-1 gene expression and peptide release in a dose-dependent manner from ECs (Figure 3a and b) indicates one of the ways in which HU exerts beneficial effects in SCA.
The effect of HU on the downregulation ET-1 expression (further supported by our unpublished observations that SCA patients under HU have significantly lower plasma ET-1 levels) if confirmed in vivo, might offer novel therapeutic strategies for sickle cell disease. Furthermore, the two-fold reduction in IL-6 production by the HU-exposed ECs ( Figure  6d ) may stem from the suppression of ET-1 expression. Previous studies show that ET-1 can induce IL-6 expression in human endothelial cells. 27 Alternatively, HU may have a direct effect on IL-6 expression. Induced secretion of IL-6 by ECs is associated with increased cell permeability, generation of reactive oxygen species and transmigration of monocytes through endothelium 28 presumptively causal for vasoendothelial injury. Again the beneficial effects of HU in SCA may be mediated through its effect on IL-6 either directly or through suppression of ET-1 expression.
We also examined the effect of HU on the expression of NO, an important component of the vasomotor regulation. HU is believed to be a chemical donor of NO, 29, 30 a potent vasodilator, and NO seems to provide a variety of beneficial effects in SCA: (i) low-dose inhalation of NO increases the oxygen affinity of sickle red cells both in vivo and in vitro, 31 (ii) NO inhalation at 20 ppm seems to provide a rapid protection against severe hypoxic stress in a transgenic mice model for SCD, 32 (iii) in SCA patients with ACS, inhaled NO improves ventilation-perfusion matching 33 and (iv) SCA patients with elevated levels of NO metabolites report lower pain scores. 34 NOS tightly regulates the NO expression in endothelial cells. We did not observe any alteration in the level of NO metabolites or changes in the endothelial expression of NOS either at transcriptional or protein level in HU-treated ECs, which suggests that the HU effect may not be mediated by this pathway.
HU Upregulates mbICAM-1 Expression and sICAM-1 Release (mbICAM-1 or CD54) is a cell surface glycoprotein of the immunoglobulin superfamily with multiple immune response-related functions, which include cell-cell interactions and leukocyte adhesion to vascular endothelial cells. The latter event initiates transmigratory egress of leukocytes from the vasculature. ICAM-1 performs these functions through its ability to bind b 2 integrins such as LFA-1 and Mac-1. Expressed constitutively in several cell types including vascular EC, the level of expression of mbICAM-1 is markedly upregulated by inflammatory stimuli such as TNFa and IFNg. 35 mbICAM-1 also acts as a major cell-surface receptor for rhinovirus and Plasmodium falciparum. 36 In addition, ICAM-1/LFA-1 interaction seems to promote HIV-1 infectivity. 37 An sICAM-1 containing most of the extracellular portion of mbICAM-1 is detectable in normal plasma. The sICAM-1 level may reflect the expression status of mbICAM-1 on endothelial cells thereby indicating the degree of inflammatory process and/or EC activation. 38 Elevated serum sICAM-1 levels have been noted in various immune and inflammatory disorders including SCA. 39 Indeed, sickle RBCs have been shown to induce mbICAM-1 expression by endothelial cells in culture both in stationary and flow studies. 40 Under flow conditions, upregulation of mbICAM-1 involves both transcriptional and translational control. sICAM-1 levels are higher (two-to three-fold) in children with SCA than in ethnically matched controls. 39 Our in vitro experimental finding that HU enhances the expression of mbICAM-1 by endothelial cells in culture (Figure 6a and b) does not appear to be consistent with the significant clinical benefits conferred by this drug in SCA patients. The strongest correlation was found between total white cell count and severity of crisis rather than with erythrocyte-related parameters. Although there is no evidence showing that ICAM-1 is directly involved in sickle cell adhesion to endothelial cells, it is plausible that leukocyteendothelium adhesion may initiate the sequestration and entrapment of RBCs resulting in the obstruction of the microvascular lumen. Accordingly HU-enhanced mb ICAM-1 expression would be expected to aggravate rather than to attenuate the sickle cell crisis. An explanation for this paradox may come from the HU-induced increase in sICAM-1 (Figure 6c ). Indeed sICAM-1 and soluble selectins have been shown to suppress significantly the neutrophilendothelial adhesion in vitro. 41 Thus, the beneficial effect of HU may be mediated through enhanced release of soluble adhesive receptors, which compete with the membranebound receptor for leukocytes and thereby minimize the vascular adhesion.
How sICAM-1 is generated is still unclear. Two possibilities are: (i) differential splicing of ICAM-1 mRNA 42 and (ii) proteolytic cleavage of mbICAM-1. 43 Distinct mRNA species encoding sICAM-1 have been identified in several human cell lines, which support the first possibility. However, and in support of the second possibility, the generation of sICAM-1 from neutrophil mbICAM-1 by elastase has been demonstrated. 44 Whatever the mechanism, the HU-induced enhancement of the release/synthesis of soluble ICAM-1 may participate in the beneficial effects of this drug. Thus, targeted antiadhesion therapies may become a useful alternative in the treatment of SCA.
HU Downregulates VCAM-1 Expression VCAM-1, like the ICAM-1, belongs to the immunoglobulin superfamily and exists in both membrane-bound (mbVCAM-1) and soluble (sVCAM-1) forms. VCAM-1 whose expression in ECs is upregulated by proinflammatory cytokines is the receptor for the very late activation antigen 4 (VLA-4, a 4 b 1 ), 45 expressed, only on the sickle erythrocyte membranes. 46 ECs stimulated by cytokines exhibit increased levels of surface adhesion molecules that could be specifically blocked by antibodies to VLA-4 and VCAM-1. Adhesion results in morphological damage to endothelium, the extent of which correlates with the number of adherent sickle erythrocytes. 47 Similarly, hypoxia significantly and specifically increases sickle erythrocyte adhesion to aortic and retinal capillary ECs without having any effect on normal erythrocytes. 48 The enhanced adhesion of sickle erythrocytes under hypoxia is accompanied by upregulation of expression of both VCAM-1 and ICAM-1. 40 The expression of these surface adhesion molecules is downregulated in vivo in mouse model by sulfasalazine, a powerful inhibitor of activation of nuclear factor kappa B (NFkB). 49 In SCA patients, a significantly high concentration of sVCAM-1 has been reported; however, HU treatment does not seem to affect the sVCAM-1 level. 50 Our experimental observation that HU downregulates VCAM-1 gene expression and mbVCAM-1 production in a dose-dependent manner, especially in the presence of cytokines (Figures 8a, b and 9b and 9b) , contrasts with what was observed for ICAM-1 expression. However, HU did not promote the release of sVCAM-1. Such downregulation of mbVCAM-1, although modest, could contribute to the attenuation of SS RBC-endothelium adhesion.
The molecular mechanisms by which HU differentially regulates the ICAM-1 and VCAM-1 gene expression are not clear, although the promoters of both genes have, binding sites for several transcription factors including NFkB, AP-1, AP-2, AP-3, and GATA in their 5 0 regulatory regions. 51, 52 Interestingly, HU prevented the binding of NFkB to the HIV-1 LTR region, which might explain the downregulation of VCAM-1, but not the upregulation of ICAM-1.
HU and Malaria
ICAM-1 is the major cell-surface receptor on vascular endothelial cells for Plasmodium falciparum-infected RBC. 53 As HU upregulates mbICAM-1 expression, it may promote RBC-endothelium adhesion and promote the progression of malaria. Hence, the administration of HU to patients from endemic areas for malaria warrants caution. Alternatively, as discussed above for SCA, the enhanced release of sICAM-1 may tend to mitigate such effects and eventually be beneficial. At present, cytoadherence experiments are underway to clarify the value of using HU in areas endemic for malaria.
HU and Cell Cycle Changes
Given the fact that HU is a S-phase blocking agent, the above-discussed HU-induced changes in EC phenotype and gene expression could be the result of cell cycle changes. To explore this possibility, cell cycle studies were performed. In our experimental conditions around 20-30% of the cells are arrested at the G1/S border and the observed changes in the expression status of ECs could be because of the accumulation of such cell subpopulation. However, the proinflammatory cytokines did not have any effect on the proportion of cells in S phase, but they do affect the expression status of cell surface and soluble adhesion molecules (ICAM-1 and VCAM-1) of ECs. This suggests that cell cycle changes alone cannot explain the changes in the expression of these molecules. Whatever the mechanism of action of HU, either through its action on gene expression or on cell cycle or both, this study provides further insight into the effect of HU on endothelial cells. Deciphering the transcriptional signature of HU in ECs may shed further light on the mechanism of action of HU and thereby provide clues to other treatment options for SCA.
METHODS
Endothelial Cell Culture
Two types of ECs were studied and were maintained at 371C with 5% carbon dioxide in a humidified incubator. Transformed human bone marrow endothelial cells (TrHBMEC), kindly provided by B Weskler, were cultured on gelatin-coated Petri dishes as previously described. 15 For this cell line, all experiments were carried out between passage 20 and 24. The cell line EA-hy 926 (epithelial/ endothelial hybrid cell line), a gift from CS Edgell, were cultured under the experimental conditions described previously. 16 Both cell types were grown until confluence and then the basal medium was replaced by a medium containing HU at various concentrations (62.5, 125, 250 and 500 mM) in the presence or absence of a mixture of TNFa and IFNg (R&D System, Abingdon, UK) each at 100 U/ml and incubated for 48 h, unless otherwise indicated.
Flow Cytometry for Cell Cycle Analysis
TrHBMEC cells and EA-hy 926 were grown as described above and treated with 250 mM HU for 24 and 48 h in three independent experiments both in the presence and absence of proinflammatory cytokines (TNFa and IFNb at 100 U/ml).
Downregulation of endothelin-1 and upregulation of ICAM-1 gene expressions
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Cells were fixed with 100 ml of ice-cold 70% ethanol for 10 min at 41C. Cells were spun for 5 min at 200 rpm and then 100 ml of PBS-RNAse A (Sigma, Saint Louis, MO, USA) at 20 mg/ml was added and cells were incubated for 30 min at room temperature. Then, 200 ml of PBS-propidium iodide (Sigma, Saint Louis, MO, USA) at 75 mg/ml was added and cells were incubated for 15 min at room temperature. A total of 10 000 cells were analyzed in an Epics-Elite flow cytometer (Coulter Electronic, Hialeah, FL, USA).
ET-1, sICAM-1, IL-6 and sVCAM-1 Assay Culture supernatants were spun for 10 min at 10 000 g at 41C, frozen at À201C in several aliquots (500 ml) until assay for ET-1, sVCAM, IL-6 and sICAM by ELISA (commercially available kits BBE5, BBE3, D6050, and BBE 1B assay Kit, R&D System, Abingdon, UK). The results for the supernatant from 5 Â 10 5 plated cells are expressed in pg/ml for ET-1 and in ng/ml for sICAM-1, IL-6 and sVCAM-1.
RNA Extraction and Reverse Transcription
Total RNA was extracted from the cultured cells using a commercial kit (RNeasy, Qiagen, Valencia, CA, USA). Briefly, 50 ml of the RNA preparation was mixed with 10 U of RQ1 RNAse free DNAse (Promega, Madison, WI, USA) and incubated for 30 min at 371C in the presence of DNAse buffer. Aliquots of 3 mg of RNA were annealed to 80 pg of random primer mixture (Life Technologies, Grand Island, NY, USA) at 701C for 10 min and then the tubes were placed in ice. The reverse transcription reaction in a final volume of 50 ml, containing 10 ml of 5 Â RT buffer, 8 ml of 100 mM dithiothreitol, 1 ml (40 U) of RNAsin (Promega, Madison, WI, USA) and 4 ml of 25 mM dNTPs, was initiated by adding 200 U of Superscript II reverse transcriptase from Moloney Murine Leukemia Virus (Life Technologies Grand Island, NY, USA) and incubated for 1 h at 371C. The reaction was stopped by incubating the reaction mixture at 701C for 10 min. The tubes were stored at -201C until the quantitative PCR assay. 
Normalization of the Quantitative PCR Data
Prior to quantitative analysis of the samples, a standard curve for threshold cycle (C T ) vs amount of RNA (for each cell type) was established to account for the differences in PCR efficiency between the test ET-1, ICAM-1, VCAM-1 mRNA and the control (TBP) mRNA. For this purpose, RNA concentrations of 1, 10, 100 pg and 1 ng (diluted with a solution of tRNA to keep the total RNA concentration constant) were used. Slopes of the standard curves generated were always between 3.2 and 3.6 corresponding to a PCR efficiency of 85-90% with a correlation coefficient consistently higher than 0.9. The variations in C t for TBP mRNA did not exceed one between experiments. For each sample, the test/TBP mRNA ratio was calculated and the results are given as the percentage of relative expression in treated vs nontreated cells.
Flow Cytometry Analysis for mbICAM-1 and mbVCAM-1 Expression Cells (final cell density of 5 Â 10 5 cells/ml) were incubated for 2 h at 41C in 100 ml PBS containing 3% fetal calf serum (FCS) both in the presence and absence of 1 mg of ICAM-1 and VCAM-1 antibodies (R&D System, Abingdon, UK). Then the cells were washed, resuspended in the same buffer in the presence of 100 ml FITC-labeled goat anti-mouse Igs and incubated at 41C for 1 h in the dark. After three washes with PBS containing 3% of FCS, the cells were fixed with 500 ml of 4% paraformaldehyde and a total of 5000 cells were analyzed in an Epics-Elite flow cytometer (Coulter Electronic, Hialeah, FL, USA). Results are expressed as MFI.
NO and NO Synthase
Both nitrites and nitrates, as indirect measures of NO, were assessed in the culture supernatants using the Griess reaction. 17 The eNOS in cell lysates were determined by ELISA using a commercial kit (R&D System, Abingdon, UK). To explore the expression of the iNOS gene, we carried out a real-time quantitative PCR with Syber Green probe using the following primers : forward primer iNOS (c) 5
0 -GGACCA-CATCTACCAGGAGGAG-3 0 and reverse primer iNOS (d) 5 0 -CCTGAACATAGACCTTGGGCT-3 0 , which allowed amplification of a 111 bp fragment encompassing the sequence of exon 25.
Statistics
Statistical analysis was performed with the nonparametric Mann-Whitney test using GraphPad Prism (Graph Pad Software, San Diego, CA, USA) and a difference between the groups was considered significant when Po0.05.
